The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2
Abstract
PURPOSE: The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 and BRCA2. This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes. MATERIALS AND METHODS: Samples of breast cancers obtained from the International Breast Cancer Linkage Consortium were characterized morphologically and immunohistochemically using antibodies to estrogen receptor, progesterone receptor, HER-2 (c-erbB-2 oncogene), and p53 protein. RESULTS: Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls. CONCLUSION: BRCA1 has a distinctive morphology and immunohistochemical phenotype. The combined morphologic and immunohistochemical data can be used to predict the risk of a young patient harboring a germline mutation in BRCA1. The BRCA2 phenotype is currently not well defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
(1967) · Project Euclid (Cornell University) · Cited by 4,720
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Self-citationDissociation between steroid receptor expression and cell proliferation in the human breast.
Clarke, R. B., Howell, A., Potten, C. S., & Anderson, E. J. (1997) · PubMed · Cited by 625
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Lenoir, G. M., Tonin, P., Linder-Stephenson, L., Salerno, G., Conway, T. A., & Lynch, H. T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4<697::aid-cncr16>3.0.co;2-w · Cited by 454
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation
Connor, F., Bertwistle, D., Mee, P. J., Ross, G. M., Swift, S., Grigorieva, E., Tybulewicz, V. L. J., & Ashworth, A. (1997) · Nature Genetics · doi:10.1038/ng1297-423 · Cited by 432
Tumour biological features of BRCA1-induced breast and ovarian cancer
Jóhannsson, Ó. T., Idvall, I., Anderson, C., Borg, Å., Barkardóttir, R. B., Egilsson, V., & Olsson, H. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89007-7 · Cited by 345
BRCA-associated breast cancer in young women.
Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., Lesser, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 302
Antoniou, A. C., Pharoah, P. D. P., McMullan, G., Day, N. E., Ponder, B. A. J., & Easton, D. (2001) · Genetic Epidemiology · doi:10.1002/gepi.1014 · Cited by 289
Self-citationArmes, J. E., Egan, A. J. M., Southey, M. C., Dite, G. S., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Venter, D. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2335::aid-cncr13>3.0.co;2-n · Cited by 259
Armes, J. E., Trute, L., White, D., Southey, M. C., Hammet, F., Tesoriero, A. A., Hutchins, A., Dite, G. S., McCredie, M. R. E., Giles, G. G., et al. (1999) · PubMed · Cited by 236
Lakhani, S. R., Gusterson, B. A., Jacquemier, J. D., Sloane, J. P., Anderson, T. J., van de Vijver, M. J., Venter, D. J., Freeman, A., Antoniou, A., McGuffog, L., et al. (2000) · PubMed · Cited by 222
Self-citationGreenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 196
The relationship between prognostic and predictive factors in the management of breast cancer
Henderson, I. C., & Patek, A. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006141703224 · Cited by 184
Liu, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.851 · Cited by 184
Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yulug, I., Peto, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202106 · Cited by 179
Self-citationp53 mutations in BRCA1-associated familial breast cancer
Crook, T., Crossland, S., Crompton, M. R., Osin, P., & Gusterson, B. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63327-2 · Cited by 179
Self-citationGerm line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer.
Eisinger, F., Stoppa‐Lyonnet, D., Longy, M., Kerangueven, F., Noguchi, T., Bailly, C., Vincent‐Salomon, A., Jacquemier, J. D., Birnbaum, D., & Sobol, H. (1996) · PubMed · Cited by 171
Self-citationPrognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006163101948 · Cited by 132
Smith, P. D., Crossland, S., Parker, G. A., Osin, P., Brooks, L. A., Waller, J., Philp, E., Crompton, M. R., Gusterson, B. A., Allday, M. J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202565 · Cited by 103
Self-citationInherited BRCA2 mutation associated with high grade breast cancer
Agnarsson, B. A., Jonasson, J. G., Björnsdottir, I. B., Barkardottir, R. B., Egilsson, V., & Sigurdsson, H. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1005853022804 · Cited by 94
Developmental Studies of Brca1 and Brca2 Knock-Out Mice
Hakem, R., de la Pompa, J. L., & Mak, T. W. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018792200700 · Cited by 91
Pathobiologic characteristics of hereditary breast cancer
Lynch, B. J., Holden, J. A., Buys, S. S., Neuhausen, S. L., & Gaffney, D. K. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90427-0 · Cited by 87
Role of BRCAgene dysfunction in breast and ovarian cancer predisposition
Scully, R. (2000) · Breast Cancer Research · doi:10.1186/bcr76 · Cited by 81
Brca2 hereditary breast cancer pathophenotype
Marcus, J. N., Watson, P., Page, D. L., Narod, S. A., Tonin, P. N., Lenoir, G., Serova, O., & Lynch, H. T. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005830230664 · Cited by 77
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers
Osin, P., Gusterson, B. A., Philp, E., Waller, J., Bártek, J., Peto, J., & Crook, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00248-2 · Cited by 57
Self-citationHormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers
Osin, P., Crook, T., Powles, T. J., Peto, J., Gusterson, B. A., & Gusterson, B. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24020-7 · Cited by 55
Self-citationNovel indications forBRCA1 screening using individual clinical and morphological features
Eisinger, F., Noguès, C., Guinebreti�re, J.-M., Peyrat, J., Bardou, V.-J., Noguchi, T., Vennin, P., Sauvan, R., Lidereau, R., Birnbaum, D., et al. (1999) · International Journal of Cancer · Cited by 54
Self-citationRudolph, P., Alm, P., Olsson, H. L., Heidebrecht, H.-J., Fernö, M., Baldetorp, B., & Parwaresch, R. M. (2001) · Human Pathology · doi:10.1053/hupa.2001.22748 · Cited by 41
BRCA1-p53 relationship in hereditary breast cancer
Sobol, H., Stoppa‐Lyonnet, D., Paillerets, B. B., Peyrat, J. P., Guinebretière, J., Jacquemier, J. D., Eisinger, F., & Birnbaum, D. (1997) · International Journal of Oncology · doi:10.3892/ijo.10.2.349 · Cited by 25
Self-citation
Cited by
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Metadata
- Authors
- Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-01
- Volume
- 20
- Issue
- 9
- Pages
- 2310-2318
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142491513
- Cited by
- 823
- References
- 35
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.